1. Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome
- Author
-
Walentyna Zoch-Zwierz and Anna Wasilewska
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Nephrotic Syndrome ,Adolescent ,CD3 Complex ,Urinary system ,Urine ,chemistry.chemical_compound ,Glucocorticoid receptor ,Receptors, Glucocorticoid ,Prednisone ,Internal medicine ,medicine ,Humans ,Lymphocyte Count ,Child ,Glucocorticoids ,Dose-Response Relationship, Drug ,business.industry ,Glomerulonephritis ,General Medicine ,medicine.disease ,Vascular endothelial growth factor ,Endocrinology ,chemistry ,Case-Control Studies ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business ,Nephrotic syndrome ,Glucocorticoid ,medicine.drug - Abstract
Aim: The aim of the study was to assess plasma and urine concentrations of vascular endothelial growth factor (VEGF) in nephrotic syndrome children (NS) depending on the total dose of glucocorticoids (GC) and the percentage of lymphocytes with glucocorticoid receptor expression (CD3/GCR). Methods: We examined 51 children (2–15 years), allocated to three groups: group I: 13 children with the first NS onset, group II: 13 children with NS relapse, group C: 25 healthy children. The NS patients were examined: (A) before treatment and (B) 4–5 weeks after prednisone administration at a dose of 60 mg/m2/24 h. Plasma and urinary VEGF levels were determined using the immunoenzymatic ELISA method. Flow cytometry was applied to assess CD3/GCR expression. Results: Higher plasma and urinary VEGF concentrations were noted in NS children before treatment (A), as compared to control subjects (C). Following prednisone therapy (B), VEGF level was reduced but it was still higher than in the control group. Positive correlation was observed between VEGF and protein in the urine (group I r = 0.660, P
- Published
- 2006